Zobrazeno 1 - 5
of 5
pro vyhledávání: '"L D, Shkolnik"'
Autor:
Yu. V. Vasyuk, V. V. Nesvetov, E. L. Shkolnik, L. D. Shkolnik, G. V. Varlan, G. E. Gendlin, E. I. Emelina
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 13, Iss 2, Pp 184-190 (2017)
Aim. To study the efficacy of ivabradine in the prevention of cardiotoxic effects due to chemotherapeutic drugs in patients with breast cancer. Material and methods. The open randomized uncontrolled study included 55 patients with breast cancer who h
Externí odkaz:
https://doaj.org/article/ac349014a6fe4c64b4fc8ed37404bd49
Publikováno v:
КардиоСоматика, Vol 4, Iss 4, Pp 20-24 (2013)
Recent years have seen significant progress in the treatment of many oncologicaldiseases associated with the development of new chemotherapeutic agents. Typically, they are used in combination with classical chemotherapy regimens that in-clude doxoru
Externí odkaz:
https://doaj.org/article/3e918cdb1e3f4e50ad05342ec304c0ee
Autor:
L. D. Shkolnik, E. I. Emelina, Yu. V. Vasyuk, V. V. Nesvetov, E. L. Shkolnik, G. V. Varlan, G. E. Gendlin
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 13, Iss 2, Pp 184-190 (2017)
Aim. To study the efficacy of ivabradine in the prevention of cardiotoxic effects due to chemotherapeutic drugs in patients with breast cancer. Material and methods. The open randomized uncontrolled study included 55 patients with breast cancer who h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e86bbda83b5bf92915f554d8a9276932
https://www.rpcardio.com/jour/article/view/1443
https://www.rpcardio.com/jour/article/view/1443
Publikováno v:
Russian Heart Failure Journal. 17:383-387
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65a946c0e6271a60a39b3a102e6cb31e
https://doi.org/10.18087/rhfj.2016.6.2327
https://doi.org/10.18087/rhfj.2016.6.2327
Publikováno v:
Kardiologiia. 56(12)
Anthracyclines including doxorubicin, epirubicin, daunorubicin, aclarubicin are extensively used as chemotherapeutic agents for treatment of hematological and other malignancies. In cancer therapy anthracyclines are often used in combinations with ot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b951dec37fc7cf42760929b88e744a6c
https://pubmed.ncbi.nlm.nih.gov/28290807
https://pubmed.ncbi.nlm.nih.gov/28290807